AbbVie stock weekly forecast: Remains supported above the 20-day average

Traders Union
All News
Stocks
AbbVie rises 0.09% this week

Highlights

Shares of AbbVie rose $0.53 over the past 7 days to $286.11, trading above short-term moving averages.
The stock maintains a bullish long-term structure with firm price action near the upper end of its recent range.
Support is at $278.78 with resistance at $289.59, and the expected trading range for next week is $281.27 to $290.94.

FDA approval and major stake increase boost sentiment this week

AbbVie received approval from the U.S. Food and Drug Administration for a subcutaneous induction regimen of SKYRIZI (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease on October 23, 2026, according to Quantisnow. In addition, Citadel Advisors significantly increased its stake in ABBV to approximately $909 million during the second quarter, CEOWORLD Magazine reported. The company is also set to release third-quarter 2026 earnings on October 30.

Momentum remains firm over the week as price holds above key averages

On the daily chart, AbbVie displays a sustained move higher with a firm trend, supported by a 3.88% volatility over the past week. Price action sits closer to the upper end of its recent range and finds solid backing above the 20-day average. Momentum readings are mixed, with the RSI at 65.09 and CCI at 83.16 both in neutral zones, while the MACD indicates buy direction and strength. Immediate support stands at $278.78 and resistance at $289.59, with the Ichimoku Kijun also acting as support at $274.83.

Upside bias prevails for next week amid potential for breakout above resistance

Next week, the expected range is $281.27 to $290.94, with a very high probability of an increase and a very low probability of a decrease. The base case sees continued consolidation between support at $278.78 and resistance at $289.59. A clear breakout above $289.59 could open further short-term upside, while a slip below $278.78 would shift the focus toward support at the Ichimoku Kijun at $274.83.

Viktoras Karapetjanc, expert at Traders Union, sees continued strength for shares of AbbVie as buyers keep the uptrend intact near $286. He highlights that recent FDA approval news for SKYRIZI and a substantial stake increase by Citadel Advisors provide a solid fundamental backdrop. Technicals remain supportive this week, with price action near the highs, daily momentum indicators neutral to positive, and strong support at $278.78. The analyst expects consolidation within $278.78–$289.59, but believes a breakout above $289.59 could open more upside, especially with upcoming earnings keeping sentiment strong. "The bullish structure remains intact, and I see further growth potential for ABBV in the coming week as positive fundamentals and technical momentum align."

Earlier, analysts noted that AbbVie's sustained technical momentum and positive clinical developments were key drivers supporting a bullish outlook for the stock. The latest FDA approval and increased institutional investment add new catalysts, making a potential breakout above $289.59 a key level to watch in the near term.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.